Galena Biopharma (GALE) : Zacks Investment Research ranks Galena Biopharma (GALE) as 1, which is a Strong Buy recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2, which indicates as a Buy.
For the current week, the company shares have a recommendation consensus of Buy. Galena Biopharma (NASDAQ:GALE): The stock opened at $0.44 on Thursday but the bulls could not build on the opening and the stock topped out at $0.44 for the day. The stock traded down to $0.40 during the day, due to lack of any buying support eventually closed down at $0.41 with a loss of -6.12% for the day. The stock had closed at $0.43 on the previous day. The total traded volume was 5,497,350 shares.
In a related news,The officer (Former Chief Financial Officer) of Galena Biopharma, Inc., Dunlap Ryan sold 126,875 shares at $2.18 on June 1, 2016. The Insider selling transaction had a total value worth of $276,588. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.